Last updated: March 19, 2026
What is the scope of the case?
Celgene Corporation filed a patent infringement case against MSN Laboratories in the District of Delaware (Case No. 1:21-cv-01795). The dispute concerns the alleged infringement of U.S. Patent No. 9,687,767, titled "Methods of Treating Hematologic Malignancies," related to Celgene’s drug Revlimid (lenalidomide). The patent claims cover methods of treating multiple myeloma using specific dosage regimens.
When was the case filed?
The case was initiated on August 25, 2021. Celgene alleges MSN Laboratories is importing, selling, and offering for sale generic versions of Revlimid without authorization, infringing on the '767 patent.
What are the key patents involved?
The patent at the center is U.S. Patent No. 9,687,767, issued on June 27, 2017, with an expiration date estimated around 2032, assuming no extensions. The patent claims focus on methods of administering lenalidomide in multiple doses for multiple myeloma treatment.
What are the main allegations?
Celgene alleges MSN Laboratories infringes the '767 patent by manufacturing and distributing generic lenalidomide products. The company claims that MSN's generic product line violates claims related to specific dosing schedules for treating cancer. Celgene seeks injunctive relief, damages for patent infringement, and an order requiring MSN to cease infringing activities.
What procedural actions have occurred?
- Preliminary Injunction Requests: Celgene has requested a preliminary injunction to halt MSN's sales of infringing products.
- Claim Construction: The court scheduled a Markman hearing to interpret patent claim terms.
- Counsel Filings: Both parties have submitted briefs elaborating their positions on patent scope and infringement issues.
- Discovery Schedule: The court set timelines for exchanging documents and conducting depositions, with trial expected in late 2023 based on typical timelines.
What defenses has MSN Laboratories raised?
MSN Laboratories argues the '767 patent is invalid due to obviousness, lack of novelty, and indefiniteness. The defendant also claims the patent claims are not infringed because their generic product uses a different dosing regimen, and the patent claims are improperly construed.
What is the potential impact?
Celgene's suit aims to restrict MSN’s sales of generic lenalidomide and preserve market exclusivity. A favorable ruling, particularly on the validity and infringement issues, could delay the entry of MSN’s generic products.
Market and industry context
The case occurs amid increasing patent challenges faced by originator pharmaceutical companies as patents for major drugs near expiration. Patent litigation often delays generic entry, impacting drug pricing and market competition.
Status as of latest update
The court has not yet issued a final ruling. The case is moving through claim construction and discovery phases. A trial date may be set for late 2023 or early 2024.
Key Takeaways
- Celgene seeks to prevent MSN Laboratories from launching a generic version of Revlimid based on patent infringement claims.
- The disputed patent covers specific dosage regimens for treatment of multiple myeloma.
- MSN Laboratories challenges patent validity and argues non-infringement.
- The outcome will influence market access for generics and could impact Revlimid’s pricing.
FAQs
1. What is the primary legal issue in this case?
The case centers on whether MSN Laboratories infringes Celgene’s patent, and whether the patent is valid under U.S. patent law.
2. How long could this litigation delay generic Revlimid?
Patent litigation typically lasts 1-3 years, suggesting potential delays until late 2023 or 2024 for generic entry.
3. What are the chances of patent invalidation?
MSN’s defenses on obviousness and novelty have legal merit, but a court’s decision depends on evidence presented during discovery and trial.
4. Does the case affect other similar drugs?
Yes. Outcomes could influence patent strategies for other oncology drugs with similar treatment claims.
5. Are there settlement options?
Parties may negotiate a settlement or licensing agreement before trial, but no such developments are publicly reported as of now.
References
[1] United States Patent and Trademark Office. (2017). Patent No. 9,687,767.
[2] District of Delaware. Case No. 1:21-cv-01795.
[3] Celgene Corporation. (2021). Complaint for patent infringement.
